Eurocine Vaccines receives grant from Merck Group

Eurocine Vaccines AB (publ) (“Eurocine Vaccines” or the “Company”) announces today that the Company has received a grant of SEK 300,000 from Merck Group (“Merck”).

Merck regularly conducts and sponsors grant programs throughout different regions of the world to enable emerging biotech companies to meet the challenges they face in bringing the next generation drugs to market. Eurocine Vaccines was chosen based on their broad portfolio of vaccine candidates. Eurocine Vaccines will be able to use the SEK 300,000 towards Merck’s bioprocessing technologies and services to further expedite their development. 

“We are very pleased to have been selected for Merck’s local European Grant Program and Sponsorship, the grant contributes to our continued work with the development of our innovative vaccine candidates” says CEO Hans Arwidsson.

Hans Arwidsson, Ph.D., MBA

CEO of Eurocine Vaccines AB
hans.arwidsson@eurocine-vaccines.com

+46 70 634 0171

Eurocine Vaccines is a development company in the highly intense vaccine area, bridging the gap between innovation and market.

Through its portfolio strategy, innovative vaccine candidates are given the opportunity to reach the market quicker, while investors are offered risk diversification with a big future leverage. These candidates are later licensed to partners for commercialization.

Listed at Spotlight Stock Market, XSAT, Eurocine Vaccines, EUCI, today operates at the heart of the bio-scientific cluster of Karolinska Institutet, Solna, Sweden and has attracted several internationally merited vaccine specialists to its board.